中国畜牧兽医 ›› 2021, Vol. 48 ›› Issue (7): 2617-2626.doi: 10.16431/j.cnki.1671-7236.2021.07.038

• 基础兽医 • 上一篇    下一篇

鸢尾黄素作为MgrA抑制剂对小鼠金黄色葡萄球菌肺炎的治疗作用

苏立燕1, 王莉2, 吴佳岂2, 关舒函2, 王大成2, 王琳1   

  1. 1. 吉林大学动物医学学院, 人兽共患病研究教育部重点实验室, 长春 130062;
    2. 吉林大学动物科学学院, 长春 130062
  • 收稿日期:2021-02-24 出版日期:2021-07-20 发布日期:2021-07-15
  • 通讯作者: 王琳 E-mail:32266914@qq.com
  • 作者简介:苏立燕(1995-),女,陕西安康人,硕士生,研究方向:兽医药理学,E-mail:1097247222@qq.com
  • 基金资助:
    吉林省自然科学基金(20180101276JC)

Therapeutic Effect of Tectorigenin as MgrA Inhibitor on Staphylococcus aureus-induced Pneumonia in Mice

SU Liyan1, WANG Li2, WU Jiaqi2, GUAN Shuhan2, WANG Dacheng2, WANG Lin1   

  1. 1. Key Laboratory of Zoonosis Research Ministry of Education, College of Veterinary Medicine, Jilin University, Changchun 130062, China;
    2. College of Animal Science, Jilin University, Changchun 130062, China
  • Received:2021-02-24 Online:2021-07-20 Published:2021-07-15

摘要: 本研究旨在从中药小分子库中筛选出金黄色葡萄球菌(Staphylococcus aureus)转录调控因子MgrA的单体抑制剂,并探讨其对金黄色葡萄球菌主要毒力因子的影响及对小鼠金黄色葡萄球菌肺炎的治疗作用。使用荧光各向异性分析法进行抑制剂的筛选,通过实时荧光定量PCR、溶血试验及纤维蛋白原黏附试验考察药物对MrgA调控的相关毒力基因转录表达及对溶血和黏附的抑制作用,采用热稳定迁移试验对其抑制机制进行初步探讨,最后通过建立小鼠肺炎模型评估鸢尾黄素对金黄色葡萄球菌诱导的小鼠肺炎的治疗作用。结果显示,鸢尾黄素作为MgrA的抑制剂,在不影响细菌生长的低浓度下(IC50=20.35 μg/mL)就能显著抑制MgrA的活性(P<0.05);实时荧光定量PCR结果显示,鸢尾黄素可显著降低fnba基因的转录水平(P<0.05),极显著降低hla和RNAⅢ基因的转录水平(P<0.01),同时极显著上调ebh、srapspa基因的转录水平(P<0.01);溶血试验显示,8 μg/mL鸢尾黄素可极显著抑制USA300菌株的溶血作用(P<0.01);纤维蛋白原黏附试验证实32 μg/mL鸢尾黄素可极显著抑制USA300菌株的黏附活性(P<0.01);热稳定迁移试验揭示了鸢尾黄素是通过与MgrA结合从而抑制其活性。小鼠肺炎试验结果显示,鸢尾黄素能极显著提高金黄色葡萄球菌感染小鼠的存活率(P<0.01),极显著减少其肺脏载菌量(P<0.01),并减轻小鼠肺脏组织的病理损伤和炎症反应。以上结果表明,鸢尾黄素能通过抑制转录调控因子MgrA的活性对金黄色葡萄球菌感染引起的小鼠肺炎起到治疗作用,可作为开发治疗金黄色葡萄球菌感染的先导化合物,并为以毒力因子MgrA为靶标的药物研发提供了理论依据。

关键词: 鸢尾黄素; 金黄色葡萄球菌; MgrA; 抑制剂; 小鼠肺炎

Abstract: The purpose of this study was to screen out the monomer inhibitors of Staphylococcus aureus transcriptional regulator MgrA from the small molecule library of traditional Chinese medicine,and explore its effect on the main virulence factors of Staphylococcus aureus and its therapeutic effect on Staphylococcus aureus-induced pneumonia in mice.Fluorescence anisotropy analysis method was used to screen inhibitors,Real-time PCR,hemolysis test and fibrinogen adhesion test were used to investigate the transcriptional expression of related virulence genes regulated by MrgA and the inhibitory effect on hemolysis and adhesion.The thermal stable migration experiment was used to preliminarily explore its inhibitory mechanism.Finally,a mouse pneumonia model was established to evaluate the therapeutic effect of Tectorigenin on Staphylococcus aureus-induced pneumonia in mice.The results showed that Tectorigenin,as an inhibitor of MgrA,could significantly inhibit the activity of MgrA at a low concentration (IC50=20.35 μg/mL) that did not affect bacterial growth (P<0.05).Real-time PCR results proved that Tectorigenin significantly reduced the transcription levels of fnba gene (P<0.05), extremely significantly reduced the transcription levels of hla and RNAⅢ genes (P<0.01),and at the same time extremely significantly increased the transcription levels of ebh, srap and spa genes (P<0.01).Hemolysis experiments showed that Tectorigenin could extremely significantly inhibit the hemolysis of USA300 strain at a concentration of 8 μg/mL (P<0.01).Fibrinogen adhesion experiments confirmed that Tectorigenin extremely significantly inhibited the adhesion activity of USA300 strain at 32 μg/mL (P<0.01).Thermal shift assay revealed that Tectorigenin inhibited its activity by binding to MgrA.The results of mouse pneumonia experiments showed that Tectorigenin could extremely significantly improve the survival rate of mice infected with Staphylococcus aureus (P<0.01),reduce the amount of bacteria in their lungs (P<0.01), and reduce the pathological damage and inflammation of lung tissue in mouse.The above results indicated that Tectorigenin could treat mouse pneumonia caused by Staphylococcus aureus by inhibiting the activity of the transcriptional regulator MgrA.Tectorigenin could be used as a lead compound for the development of treatment of Staphylococcus aureus infection,and provided a theoretical basis for the development of drugs targeting MgrA.

Key words: Tectorigenin; Staphylococcus aureus; MgrA; inhibitor; mice pneumonia

中图分类号: